The FDA declined to grant Veru Inc’s (NASDAQ: VERU) request for Emergency Use Authorization (EUA) for sabizabulin to treat hospitalized adult patients with moderate to severe COVID-19 who are at high risk for Acute Respiratory Distress Syndrome (ARDS). Separately, the FDA also commented on the company’s proposed confirmatory Phase 3 study protocol for […]